<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880331</url>
  </required_header>
  <id_info>
    <org_study_id>20193001</org_study_id>
    <nct_id>NCT03880331</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Clinical Trial Comparing Outcomes of Secondary Intention Wound Care Methods</brief_title>
  <official_title>Prospective Randomized Clinical Trial Comparing Outcomes of Secondary Intention Wound Care Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lahey Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial which is designed to determine whether aggressive and
      frequent debridement of an acute post-surgical wound shortens healing time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary intention is an established method of allowing post-surgical defects to heal.
      Previous studies have shown a positive association between the frequency of debridement and
      healing rates in chronic wounds. However, the effect of debridement on acute, post-surgical
      wounds is not well-described in the literature.

      This randomized controlled trial is designed to determine whether aggressive and frequent
      debridement of an acute post-surgical wound shortens healing time.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Blinded investigator will assess photographs of completely healed wounds</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to healing</measure>
    <time_frame>0-16 weeks</time_frame>
    <description>Time to complete healing as determined by one of the study investigators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with scar: Patient Scar Assessment Questionnaire (PSAQ)</measure>
    <time_frame>0-16 weeks. NOTE: The PSAQ will be completed by the patient once their wound is determined to be completely healed by the study investigators; usually between 6-8 weeks.</time_frame>
    <description>As assessed by the Patient Scar Assessment Questionnaire (PSAQ), a validated questionnaire used standardly in Dermatology for assessing patient-based outcome measures of scarring. It consists of 5 subscales: appearance, symptoms consciousness, satisfaction with appearance and satisfaction with symptoms. Each subscale consists of a set of items with 4-point categorical responses, scoring 1 to 4 points (with 1 point assigned to the most favorable category and 4 assigned to the least favorable). It has been demonstrated to be a reliable and valid measure of patients' perception of scarring. See reference #12 in reference list for more information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Appearance</measure>
    <time_frame>0-16 weeks. NOTE: A photograph of the the patient's final healed wound will be evaluated by a blinded investigator after the wound is determined to be completely healed by the study investigators; usually between 6-8 weeks</time_frame>
    <description>As assessed by the Visual Analog Scale, a validated image-based scale, that uses photographs for evaluation in 5 dimensions (pigmentation, vascularity, acceptability, observer comfort, and contour). &quot;Observer comfort&quot; measures the observer's &quot;comfort level&quot; when viewing the wound. The benefit of using this scale for the purposes of the study is because it is a photograph-based scale which can be evaluated later by a blinded physician rather than in the clinic at the time of the visit. The observer places a mark along a continuous line that measures 10cm long, and then that is measured from left to right and a corresponding score is given corresponding to that length (between 0 and 10). The individual scores are tallied to obtain a single overall score ranging from &quot;poor&quot; to &quot;excellent.&quot; See reference #13 in reference list for more information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of required debridements</measure>
    <time_frame>0-16 weeks</time_frame>
    <description>Number of required debridements over the course of healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment failures</measure>
    <time_frame>Through study completion, an average of 6-8 weeks</time_frame>
    <description>Number of wounds that do not heal by 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>0-16 weeks</time_frame>
    <description>Including degree of pain (on a scale of 0-10), number of episodes of bleeding, number of infection, and incidence of tumor recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Wound Surgical</condition>
  <condition>Wound Heal</condition>
  <arm_group>
    <arm_group_label>Aggressive Debridement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal Debridement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Debridement</intervention_name>
    <description>Aggressive vs Minimal Debridement</description>
    <arm_group_label>Aggressive Debridement</arm_group_label>
    <arm_group_label>Minimal Debridement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Dermatology patients at Lahey Clinic:

          2. who have undergone Mohs surgery or excision

          3. who are older than 18 years

          4. who are able to give consent

          5. who had postoperative defects allowed to heal by secondary intention on the a) head
             and neck, b) trunk and upper extremities, c) lower extremities

          6. who are willing and able to return to clinic in Peabody, MA, for all wound care visits

        Exclusion Criteria:

          1. Unable to consent (due to language barrier or mental status)

          2. Unable to perform daily wound care

          3. Unwilling or unable to return for follow-up

          4. Have baseline venous stasis or pitting edema of the affected limb

          5. Wear compression stockings or require use of a compressive bandage (such as an Unna
             Boot) at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Tiger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lahey Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lahey Medical Center Peabody</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saap LJ, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen. 2002 Nov-Dec;10(6):354-9.</citation>
    <PMID>12453138</PMID>
  </reference>
  <reference>
    <citation>Steed DL. Debridement. Am J Surg. 2004 May;187(5A):71S-74S. Review.</citation>
    <PMID>15147995</PMID>
  </reference>
  <reference>
    <citation>Hess CT, Kirsner RS. Orchestrating wound healing: assessing and preparing the wound bed. Adv Skin Wound Care. 2003 Sep-Oct;16(5):246-57; quiz 258-9.</citation>
    <PMID>14581817</PMID>
  </reference>
  <reference>
    <citation>Fonder MA, Lazarus GS, Cowan DA, Aronson-Cook B, Kohli AR, Mamelak AJ. Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol. 2008 Feb;58(2):185-206. doi: 10.1016/j.jaad.2007.08.048. Review.</citation>
    <PMID>18222318</PMID>
  </reference>
  <reference>
    <citation>Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, Woo K, Romanelli M, Kirsner RS. What's new: Management of venous leg ulcers: Treating venous leg ulcers. J Am Acad Dermatol. 2016 Apr;74(4):643-64; quiz 665-6. doi: 10.1016/j.jaad.2015.03.059. Review.</citation>
    <PMID>26979355</PMID>
  </reference>
  <reference>
    <citation>Wilcox JR, Carter MJ, Covington S. Frequency of debridements and time to heal: a retrospective cohort study of 312 744 wounds. JAMA Dermatol. 2013 Sep;149(9):1050-8. doi: 10.1001/jamadermatol.2013.4960. Erratum in: JAMA Dermatol. 2013 Dec;149(12):1441.</citation>
    <PMID>23884238</PMID>
  </reference>
  <reference>
    <citation>Luft HS. Becoming accountableâ€”opportunities and obstacles for ACOs. N Engl J Med. 2010 Oct 7;363(15):1389-91. doi: 10.1056/NEJMp1009380.</citation>
    <PMID>20925539</PMID>
  </reference>
  <reference>
    <citation>Gloster HM Jr. The use of second-intention healing for partial-thickness Mohs defects involving the vermilion and/or mucosal surfaces of the lip. J Am Acad Dermatol. 2002 Dec;47(6):893-7.</citation>
    <PMID>12451375</PMID>
  </reference>
  <reference>
    <citation>Gohari S, Gambla C, Healey M, Spaulding G, Gordon KB, Swan J, Cook B, West DP, Lapiere JC. Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg. 2002 Dec;28(12):1107-14; discussion 1114.</citation>
    <PMID>12472488</PMID>
  </reference>
  <reference>
    <citation>Dodson MK, Magann EF, Meeks GR. A randomized comparison of secondary closure and secondary intention in patients with superficial wound dehiscence. Obstet Gynecol. 1992 Sep;80(3 Pt 1):321-4.</citation>
    <PMID>1495686</PMID>
  </reference>
  <reference>
    <citation>Joo J, Custis T, Armstrong AW, King TH, Omlin K, Kappel ST, Eisen DB. Purse-string suture vs second intention healing: results of a randomized, blind clinical trial. JAMA Dermatol. 2015 Mar;151(3):265-70. doi: 10.1001/jamadermatol.2014.2313.</citation>
    <PMID>25372450</PMID>
  </reference>
  <reference>
    <citation>Durani P, McGrouther DA, Ferguson MW. The Patient Scar Assessment Questionnaire: a reliable and valid patient-reported outcomes measure for linear scars. Plast Reconstr Surg. 2009 May;123(5):1481-9. doi: 10.1097/PRS.0b013e3181a205de.</citation>
    <PMID>19407619</PMID>
  </reference>
  <reference>
    <citation>Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring devices. Eplasty. 2010 Jun 21;10:e43.</citation>
    <PMID>20596233</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lahey Clinic</investigator_affiliation>
    <investigator_full_name>Jeffrey Tiger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Secondary intention</keyword>
  <keyword>Wound care methods</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Final results will be shared with another investigator who will not be participating in the clinical trial but will author the paper. All individual participant data will be de-identified before sharing with this investigator.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become available once the final patient has finished the study and the data has been compiled and de-identified. It will be available until the paper is accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>Investigator will have access to the results as needed to author the paper.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03880331/Prot_SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03880331/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

